Innate immunity receptor CD36 promotes cerebral amyloid angiopathy

Area of Science:

• Neuroscience
• Immunology
• Vascular Biology

Background:

• Cerebral amyloid angiopathy (CAA) involves amyloid-beta (Aβ) deposition in brain arteries, linked to Alzheimer's disease and cognitive decline.
• The precise mechanisms driving CAA and potential therapeutic targets remain largely unknown.
• CD36, an innate immunity receptor, is implicated in Aβ trafficking.

Purpose of the Study:

• To investigate the role of CD36 in Aβ accumulation, neurovascular dysfunction, and cognitive deficits in a mouse model of Alzheimer's disease.
• To determine if targeting CD36 could ameliorate CAA-related pathology and cognitive impairment.

Main Methods:

• Utilized Tg2576 transgenic mice, which overexpress the Swedish mutation of the amyloid precursor protein.
• Compared Tg2576 mice lacking CD36 with wild-type and Tg2576 mice with CD36.
• Assessed Aβ deposition, LRP-1 levels, cerebral arteriole function, neurovascular regulation, and cognitive performance.

Main Results:

• Tg2576 mice lacking CD36 exhibited significantly reduced Aβ1-40 levels and cerebral amyloid angiopathy.
• Absence of CD36 preserved the Aβ vascular clearance receptor LRP-1 and protected cerebral arterioles from Aβ-induced damage.
• Mice lacking CD36 showed improved neurovascular regulation and cognitive performance compared to Tg2576 mice with CD36.

Conclusions:

• CD36 plays a critical role in promoting vascular amyloid deposition and subsequent cerebrovascular damage.
• Targeting CD36 may offer a novel therapeutic strategy for cerebral amyloid angiopathy and associated cognitive deficits.
• These findings highlight CD36 as a previously unrecognized contributor to CAA pathogenesis.